Evidence map›Paper›PMID 36146520›Full record

ArticleVaccines2022

Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccination-Results from a Serological Survey.

Nadav Zacks, Amir Bar-Shai, Hezi Levi, Anna Breslavsky, Shlomo Maayan, Tsyba Evgenia, Shlomo Feitelovich, Ori Wand, Moshe Schaffer, Yaniv Sherer and 4 more

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nadav ZacksFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.ORCID 0000-0002-0161-5360
Amir Bar-ShaiFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Hezi LeviFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Anna BreslavskyPulmonary Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Shlomo MaayanDivision of Infectious Diseases, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Tsyba EvgeniaDivision of Infectious Diseases, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Shlomo FeitelovichLaboratory Division, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Ori WandFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Moshe SchafferFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Yaniv ShererFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Gili GivatyMedical Administration Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Anat Tzurel FerberPulmonary Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
Tal MichaelFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Natalya BilenkoFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 is a novel human pathogen causing Coronavirus Disease 2019 that has caused widespread global mortality and morbidity. Since health workers in Israel were among the first to be vaccinated, we had a unique opportunity to investigate the post-vaccination level of IgG anti-S levels antibodies (Abs) and their dynamics by demographic and professional factors. Methods: Prospective Serological Survey during December 2020−August 2021 at Barzilai Medical Center among 458 health care workers (HCW) followed for 6 months after the second BNT162b2 vaccine dose. Results: Antibody levels before the second dose, and 30, 90 and 180 days after were 57.1 ± 29.2, 223 ± 70.2, 172.8 ± 73.3 and 166.4 ± 100.7 AU/mL, respectively. From GEE analysis, females had higher Abs levels (β = 26.37 AU/mL, p = 0.002). Age was negatively associated with Abs, with a 1.17 AU/mL decrease for each additional year (p < 0.001). Direct contact with patients was associated with lower Abs by 25.02 AU/mL (p = 0.009) compared to working with no such contact. The average decline rate overall for the study period was 3.0 ± 2.9 AU/mL per week without differences by demographic parameters and was faster during the first 3 months after vaccination than in the subsequent 3 months. Conclusions: All demographic groups experienced a decline in Abs over time, faster during the first 3 months. Findings of overall Abs lower in males, workers with direct contact with patients, and older workers, should be considered for policy-making about choosing priority populations for additional vaccine doses in hospital settings.

Indexed as

Barzilai Medical CenterBNT162b2 vaccinationbooster vaccinationsdemographic factorsHealth-Care-Workspatiant contectSARS-CoV-2 antibodiesvaccination regimenswaning of antibodies

Identifiers

PMID36146520
PMCPMC9503366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.